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The role of NF-B in regulating human cytomegalovirus (HCMV) replication and gene transcription
remains controversial. Multiple, functional NF-B response elements exist in the major immediate-early
promoter (MIEP) enhancer of HCMV, suggesting a possible requirement for this transcription factor in lytic
viral replication. Here we demonstrate by generating and analyzing HCMVs with alterations in the MIEP-
enhancer that, although this region is essential for HCMV growth, none of the four NF-B response elements
contained within the enhancer are required for MIE gene expression or HCMV replication in multiple cell
types. These data reveal the robustness of the regulatory network controlling the MIEP enhancer.
The major immediate-early promoter (MIEP) of human cy-
tomegalovirus (HCMV) is responsive to a multitude of tran-
scription factors and plays a pivotal role in initiating the viral
transcription/replication cycle (7, 16; reviewed in references 22
and 23). Regulation of the MIEP has been postulated to be
critical in determining HCMV permissiveness and the transi-
tion between latent and lytic infection. Thus, deciphering the
molecular mechanisms of the MIEP regulation may reveal key
control points contributing to HCMV pathogenesis.
The MIEP enhancer includes four cognate NF-B recogni-
tion sites, and NF-B activates MIEP transcription in tran-
sient-transfection assays (20, 25–27). HCMV infection results
in rapid induction of cellular NF-B (19, 27, 30), and several
groups have reported a potential contribution of NF-B to the
replication strategy of HCMV through regulation of the MIEP
(8, 13). In contrast, we and others have reported a neutral or
even a negative role of NF-B activation on HCMV transcrip-
tion/replication cycle in different cell types (3, 4, 11, 14, 15).
However, the basis for these experimental discrepancies is
currently unclear. Importantly, a direct test of the requirement
for the MIEP NF-B binding sites in HCMV transcription/
replication has still not been performed. Here we report on
formally assessing the direct requirement of the cognate bind-
ing sites for NF-B in contributing to major immediate-early
(MIE) transcription and viral growth.
As a first step toward understanding NF-B regulation of
the HCMV MIEP, we deleted enhancer sequences from 52
to 667 (including all NF-B response elements), in HCMV
AD169. A parental HCMV bacterial artificial chromosome
(BAC) (5, 6) containing the E-GFP open reading frame
(ORF) under control of the murine cytomegalovirus (MCMV)
MIEP (Fig. 1A, line 1) was used to construct two enhancerless
HCMV recombinant mutants. In HCMVdE, MIEP sequences
from 52 to 667 were removed (Fig. 1A, line 2), and in
HCMVdE::Kan, enhancer sequences were replaced with a
1-kbp stuffer region to maintain the genomic spatial integrity
of the ie1/ie2 and UL127 promoters (Fig. 1A, line 3). Once the
integrity of constructed HCMV genomes was confirmed by
restriction analysis (data not shown), they were transfected in
MRC-5 fibroblasts. Three days posttransfection, 100 single
cells expressing green fluorescent protein (GFP) could be de-
tected in all cultures (see Fig. 1B, panels D, G, and J). Cells
transfected with the parental HCMV BAC yielded viral
plaques (Fig. 1B, panel E) that progressed to complete cyto-
pathicity (panel F), whereas cultures transfected with the en-
hancerless HCMV BACs did not result in viral spread (panels
H, I, K, and L). These data indicate that deletion of the entire
MIEP enhancer region of HCMV genome is lethal.
To verify that the generated HCMV mutants were defective
due to deletion of the enhancer, the ability of an IE1/IE2
expression plasmid (pSVH) (29) to rescue replication was
tested. Cotransfection of enhancerless BACs with pSVH re-
sulted in spread of GFP-expressing virus to adjacent cells (Fig.
1B, panels M to O and P to R), ultimately leading to a com-
plete cytopathic effect. In addition, a revertant HCMVdE virus
was generated by the ET BAC mutagenesis method (5, 24) and
shown to replicate with identical kinetics to the parental
HCMV in MRC-5 cells (Fig. 1C). Thus, these results indicate
that deleting the entire MIEP enhancer in HCMV AD169
abolishes lytic viral replication in cultured fibroblasts and are
consistent with previous results resecting MIEP enhancer se-
quences in the Towne strain of HCMV (18, 21). Here, through
the rescue experiments, we have eliminated the possibility that
the replication defects seen in the enhancerless HCMV recom-
binants were due at least in part to alterations in other regions
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of their genome. These observations are also in line with the
absolute requirement of the enhancer during the acute MCMV
infection (17).
To directly analyze the role of NF-B in regulating the
MIEP, we specifically disrupted the four enhancer NF-B
binding sites. The point mutations introduced in the MIEP (3)
are illustrated in Fig. 2A. It should be noted that these four
sites are the only NF-B binding sites present in the MIE
enhancer and that, in the context of the whole genome, NF-B
recognition sites have only been described to date in another
location, the US3 immediately-early (IE) enhancer (9). Trans-
fection of human U937 cells with reporter plasmids containing
FIG. 1. Effect of a deletion of the entire MIEP enhancer on HCMV. (A) Schematic representation of the enhancerless HCMV BAC genomes
constructed. The top line represents the map of the parental HCMV BAC genome with the US1-US12 region expanded above, indicating the BAC
sequences and the E-GFP gene under control of the MCMV MIEP (mMIEP) that replace the US2-US11 region. Below, the EcoRI J fragment
(nucleotide sequences from 165498 to 175524 of the HCMV genome [28]) encompassing the HCMV MIE region is enlarged (line 1), with the
structures of the ie1 and ie2 transcripts indicated. The first noncoding exon of the ie1/ie2 transcription unit is depicted as an open rectangle, and
coding exons are shown solid. The shaded box marks the HCMV MIEP enhancer (extending from nucleotides 52 to 667 relative to the ie1/ie2
HCMV transcription start site). The two enhancerless HCMV BAC genomes, HCMVdE and HCMVdE::Kan, were derived from the parental
HCMV BAC by the ET BAC mutagenesis method (5, 6, 24). The deletion of the entire HCMV enhancer (nucleotide sequences from 174713 to
175328 of the HCMV genome) in HCMVdE (line 2) is indicated by a “” symbol. In HCMVdE::Kan (line 3), the 1-kbp fragment from the
kanamycin resistance gene that replaces the HCMV MIEP enhancer is represented by a cross-hatched box. A new EcoRI restriction site was
introduced at the location of the enhancer deletion (in HCMVdE) or the stuffer insertion (in HCMVdE::Kan) to facilitate the characterization
of the mutant genomes by an EcoRI restriction digestion (data not shown). Sizes of the natural and new EcoRI J DNA fragments for each
recombinant BAC are indicated. The illustration is not drawn to scale. (B) Transfection of HCMV enhancerless genomes in cultured fibroblasts.
MRC-5 cells were cotransfected by the calcium phosphate precipitation technique with 2 g of either HCMV (D to F), HCMVdE (G to I and M
to O), or HCMVdE::Kan (J to L and P to R) BAC DNAs together with 1 g of a vector expressing the tegument protein pp71 (2), and when
indicated with 1 g of the HCMV IE1 and IE2 expression vector pSVH (29). GFP expression was detected by fluorescence microscopy at the
indicated days after infection (dpi). Magnification, 20. (C) Growth kinetics of HCMVdE-rev. MRC-5 cells were infected at a multiplicity of
infection (MOI) of 0.025 with HCMV or HCMVdE-rev, a revertant of HCMVdE in which sequences from 52 to 667 of the MIEP were
reintroduced in the HCMVdE genome by the ET BAC mutagenesis method. At the indicated days postinfection supernatants from the infected
cultures were harvested, and titers were determined by standard plaque assays on MRC-5 cells. Each datum point represents the average and
standard deviation from three separate cultures. The dashed line represents the limit of detection.
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either the wild-type or the NF-B mutant MIEP revealed that
tumor necrosis factor alpha (TNF-)-induced MIEP activity
was abolished in the mutant, whereas basal transcription was
not affected (Fig. 2B). These results are consistent with previ-
ous studies indicating a role for NF-B in regulating MIEP
activity in transfection-based assays. To then test whether the
four cognate NF-B response elements in the MIEP are re-
quired for HCMV replication, two independent HCMV recom-
binants mutated in the NF-B binding sites were generated (HC-
MV.NFkBa and HCMV.NFkBb). HCMV.NFkBa was
constructed by using the ET mutagenesis method and subsequent
transfection of the mutant BAC in MRC-5 cells, whereas HCM-
V.NFkBb was generated by cotransfecting MRC-5 cells with HC-
MVdE, pSVH, and pUChEnh.NFkB, a plasmid that carries
HCMV sequences from nucleotide 171443 to 176844 (10) in
which the four NF-B elements of the enhancer were mutated.
Infectious recombinant viruses were recovered from the trans-
fections, used to infect new cell monolayers, and plaque puri-
fied three times. Viral stocks of both HCMV.NFkBa and HC-
MV.NFkBb were prepared, their genomic integrity was
verified by restriction digestion (data not shown), and the suc-
cessful disruption of the enhancer NF-B binding sites was
confirmed by PCR analysis (Fig. 2C) and the nucleotide se-
quence of the MIEP region (data not shown).
We next assessed the effect of abrogating the enhancer
NF-B recognition sites on expression emanating from the
MIEP in the context of the infection of human embryonic lung
(HEL) fibroblasts with either wild-type or mutant viruses. As
shown by real-time PCR, IE1 mRNA levels were comparable
or even slightly higher (48 h postinfection [hpi]) in cells in-
fected with HCMV.NFkBa and HCMV.NFkBb than in paren-
tal HCMV-infected cells (Fig. 3A). In addition, HEL cells were
infected throughout a 72-h period with the three viruses and
subjected to Western blots by using a monoclonal antibody
specific for the IE1 protein. We could not detect significant
differences in the expression of the IE1 protein between
HCMV and the HCMV.NFkB mutants at any of the time
points analyzed (Fig. 3B). Furthermore, treatment of cells with
the NF-B inducer TNF- (Fig. 3B) did not result in differ-
ential expression of IE1 in cells infected with wild-type or
mutant viruses. Consequently, we conclude that the NF-B
binding sites in the MIEP do not significantly influence ie1
gene transcription or expression in lytically infected fibroblasts.
To examine the requirement for the enhancer NF-B bind-
ing elements on HCMV growth, kinetic studies with HCMV,
HCMV.NFkBa, or HCMV.NFkBb were performed on HEL
fibroblasts. No difference in viral production at any time point
was observed between the mutants and the parental virus (Fig.
4A). Treatment of cultures with TNF- drastically inhibited
HCMV growth, likely due to the induction of beta interferon
(4; data not shown). In order to examine the replication ca-
pacity of HCMV.NFkB mutants in other cell types, we tested
lung fibroblasts (MRC-5), U373 MG cells derived from glio-
blastoma, retinal pigment epithelium (RPE) cells, and dif-
ferentiated embryonal carcinoma cells NTERA2 (NT2/D1).
Importantly, parental and mutant viruses replicated in a com-
parable manner (Fig. 4B to E), strongly suggesting a neutral
role of NF-B for HCMV acute transcription/replication cycle
in different cell types in culture.
The molecular details on the activation of the MIEP during
HCMV infection are still poorly understood. In the present
study, we demonstrate by generating and characterizing
HCMV recombinants with alterations in the MIEP enhancer
that (i) the enhancer region is necessary for HCMV growth
FIG. 2. Construction of recombinant HCMVs with point mutations
in the NF-B binding sites of the enhancer region. (A) The sequence
and location of the four NF-B binding sites within the HCMV MIEP
are shown, and the point mutations introduced in each specific element
are indicated below the wild-type sequence. Mutation of the NF-B
recognition site at position 157 to 165 generates a KpnI restriction
site at position161 to166, which is shown. Coordinates refer to the
HCMV ie1/ie2 transcription start site. (B) The structures of the lucif-
erase (Luc) reporter constructs pMIEP.Luc and pMIEPNFkB.Luc
containing MIEP sequences from 1144 to 112 (relative to the
HCMV ie1/ie2 transcription start site) without () and with (■) the
NF-B binding sites disrupted, respectively, are shown. 5 105 U937 cells
were electroporated with 2 g of pMIEP.Luc or pMIEPNFkB.Luc,
along with 0.6 g of the internal control plasmid pRL-TK, and cul-
tured for 46 h before the luciferase activity was assayed. Six hours
before harvesting, cultures were treated with TNF- (10 ng/ml; ) or
vehicle (phosphate-buffered saline; ). The results are presented
as the fold induction, taking “1” as the activity presented by the
pMIEP.Luc in the absence of TNF-. The values shown represent the
average 	 the standard deviation (bars) of four determinations.
(C) Schematic diagram of the HCMV MIEP enhancer region, with
the location of the four NF-B binding sites marked by solid boxes.
The KpnI restriction site at position 161 to 166 introduced when
the NF-B binding site located between positions 157 and 165 is
mutated is indicated, as well as the sizes of the expected KpnI frag-
ments derived from the PCR-amplified enhancer fragment with prim-
ers dN and dBlp (3) (flanking the enhancer and indicated with white
arrows). Coordinates refer to the HCMV ie1/ie2 transcription start
site. To confirm the correct mutagenesis of the NF-B binding sites,
enhancer sequences were amplified from stocks of HCMV (lanes 1 and
4), HCMV.NFkBa (lanes 2 and 5), and HCMV.NFkBb (lanes 3 and 6)
by PCR. Marked by arrows are the amplified products before (lanes 1
to 3) or after (lanes 4 to 6) digestion with KpnI resolved by gel
electrophoresis. Size markers are shown at the right margin.
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FIG. 4. Growth kinetics of HCMV.NFkB mutants. HEL (A), MRC-5 (B), RPE (C), U373 (D), and NT2/D1 cells (E; differentiated for 5 days
with 105 M retinoic acid) were infected at an MOI of 0.025 (HEL and MRC-5) or 1 (RPE, U373, and NT2/D1, resulting in ca. 10 to 25% of
GFP-positive cells in the culture at 48 hpi) with HCMV, HCMV.NFkBa, or HCMV.NFkBb. At the indicated time in days postinfection, the
amount of extracellular (HEL, MRC-5, and RPE) or cell associated (U373 and NT2/D1) infectious virus present in the cultures was determined
by plaque titration assays on MRC-5 cells. Each datum point represents the average and standard deviation from three separate cultures. Dashed
lines represent the limits of detection.
FIG. 3. Analysis of ie1 gene expression in HCMV.NFkB-infected cells. (A) Real-time PCR analysis of ie1 RNA expression in cells infected with
HCMV.NFkB. HEL fibroblasts were infected at an MOI of 0.01 with HCMV, HCMV.NFkBa, or HCMV.NFkBb and harvested at the time points
after infection indicated for isolation of RNA and subsequent analysis by real-time PCR using primers within exon 4 of the HCMV ie1 gene as
previously described (3). The results are presented as the relative amount of ie1 mRNA normalized to 18S rRNA, and error bars represent the
standard errors of the means. (B) Expression kinetics of the IE1 protein by HCMV.NFkB mutants. HEL fibroblasts were mock infected or infected
at an MOI of 0.6 (for the 4-, 6-, and 12-h time points) or 0.1 (for the 24, 48, and 72 h time points). Where indicated, cells were treated with 10
ng of TNF-/ml 2 h before infection, during, and immediately after the adsorption period. At the indicated time (in hours) postinfection (hpi),
samples were lysed, subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis on 7% gels, transferred to nitrocellulose as previously
described (1), and probed with an HCMV IE1 specific monoclonal antibody (MAB810; Chemicon, Temecula, CA). As an internal control, actin
immunodetection was performed with a monoclonal antibody (A2066; Sigma, St. Louis, MO).
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and (ii) the MIEP NF-B response elements do not contribute
to lytic replication of HCMV in multiple cell types.
The involvement of NF-B activity on MIE expression and
HCMV replication has been a controversial issue (3, 4, 8,
11–15). The discrepancy pivots around whether NF-B directly
or indirectly influences HCMV transcription and/or replica-
tion. It is generally assumed in the field that the activation of
NF-B results in the direct stimulation of the MIEP and, as a
consequence, in increased, i.e., gene expression and viral rep-
lication. Our observations are in agreement with the fact that
NF-B contributes to HCMV MIEP-enhancer activation in
transient-transfection assays, as has been documented in a
number of reports. However, we clearly show here that the
cognate NF-B binding sites within the enhancer do not play a
major independent role in the transcription/replication strate-
gies of HCMV in a variety of cell types. We demonstrate in a
direct manner that, in the context of the infection, the en-
hancer is insensitive to mutations in the NF-B binding sites,
underlining a high level of robustness of the associated regu-
latory network controlling this region. While these results are
in line with previous observations (3, 11, 14, 15), they are in
contrast with others (8, 12, 13). In these apparently contradic-
tory studies, a positive involvement of NF-B in MIEP tran-
scription and HCMV replication has been observed by block-
ing NF-B activity using a variety of pharmacologic agents
exhibiting a range of specificity and selectivity. These studies
provide an indirect test and, moreover, the selectivity of the
agents (e.g., aspirin or MG-132) used to inhibit NF-B signal-
ing pathways should be taken in consideration. It must be also
noted that although to date only NF-B sites have been found
in the MIEP and in the US3 IE enhancer (9), the presence of
additional NF-B responsive genes in the HCMV genome
could account in part for some of the discrepancies found in
different studies.
Our data do not exclude the possibility that NF-B may
regulate HCMV MIE gene expression or growth in cell types
not examined here or are required for in vivo replication
and/or reactivation from latency. The fact that the viruses used
in the present study derive from the HCMV laboratory strain
AD169 prevented their analysis in other cell types more rele-
vant for HCMV infection, including macrophages, endothelial,
or dendritic cells. Mouse CMV recombinants containing the
HCMV MIEP (with or without mutations in the NF-B re-
sponse elements) replicate and establish latency in the mouse
(1, 3; A. Angulo unpublished results), permitting us to explore
these aspects in the context of an in vivo infection.
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